File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.

TitleCyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Authors
Issue Date2003
PublisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/
Citation
International Journal Of Oncology, 2003, v. 23 n. 5, p. 1317-1322 How to Cite?
AbstractAlthough gastric cancer with cyclooxygenase (COX)-2 overexpression is associated with poor prognosis, the mechanistic pathway remains unknown. We examined the associations between expressions of COX-2 and vascular endothelial growth factor (VEGF) in both gastric cancer cells and in human gastric cancer. The gastric cell line, Kato III, was transiently transfected with cox-2 expressing vector. The levels of COX-2, prostaglandin (PG) E2 and VEGF expression were measured post-transfection. Additionally, expressions of COX-2 and VEGF in human gastric cancer were determined by immunohistochemistry in archive gastrectomy specimens. Tumor angiogenesis was assessed by the microvessel density (MVD), which was determined by anti-CD34 immunostaining. Transient transfection of Kato III with cox-2 was associated with increased COX-2 expression, higher PGE2 production and upregulated VEGF expressions. Treatment with NS398, a specific COX-2 inhibitor, reduced VEGF expression in COX-2 expressing Kato III cells by 25%. Among the 67 gastric cancers examined, COX-2 overexpression was found in 45 (67%) cases whereas increased VEGF expression was detected in 46 (69%) cases. There was a significant association between COX-2 and VEGF expressions in gastric cancer (r=0.25, p=0.041). Additionally, tumor MVD was associated with both COX-2 (r=0.32, p=0.008) and VEGF (r=0.39, p=0.001) expressions. Our results showed that overexpression of COX-2 in both gastric cells and primary gastric cancer is associated with upregulation of VEGF and angiogenesis. Future studies should evaluate the potential anti-angiogenic effect of COX-2 inhibitors on human gastric cancer.
Persistent Identifierhttp://hdl.handle.net/10722/162927
ISSN
2015 Impact Factor: 3.018
2015 SCImago Journal Rankings: 1.270
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLeung, WKen_US
dc.contributor.authorTo, KFen_US
dc.contributor.authorGo, MYen_US
dc.contributor.authorChan, KKen_US
dc.contributor.authorChan, FKen_US
dc.contributor.authorNg, EKen_US
dc.contributor.authorChung, SCen_US
dc.contributor.authorSung, JJen_US
dc.date.accessioned2012-09-05T05:25:28Z-
dc.date.available2012-09-05T05:25:28Z-
dc.date.issued2003en_US
dc.identifier.citationInternational Journal Of Oncology, 2003, v. 23 n. 5, p. 1317-1322en_US
dc.identifier.issn1019-6439en_US
dc.identifier.urihttp://hdl.handle.net/10722/162927-
dc.description.abstractAlthough gastric cancer with cyclooxygenase (COX)-2 overexpression is associated with poor prognosis, the mechanistic pathway remains unknown. We examined the associations between expressions of COX-2 and vascular endothelial growth factor (VEGF) in both gastric cancer cells and in human gastric cancer. The gastric cell line, Kato III, was transiently transfected with cox-2 expressing vector. The levels of COX-2, prostaglandin (PG) E2 and VEGF expression were measured post-transfection. Additionally, expressions of COX-2 and VEGF in human gastric cancer were determined by immunohistochemistry in archive gastrectomy specimens. Tumor angiogenesis was assessed by the microvessel density (MVD), which was determined by anti-CD34 immunostaining. Transient transfection of Kato III with cox-2 was associated with increased COX-2 expression, higher PGE2 production and upregulated VEGF expressions. Treatment with NS398, a specific COX-2 inhibitor, reduced VEGF expression in COX-2 expressing Kato III cells by 25%. Among the 67 gastric cancers examined, COX-2 overexpression was found in 45 (67%) cases whereas increased VEGF expression was detected in 46 (69%) cases. There was a significant association between COX-2 and VEGF expressions in gastric cancer (r=0.25, p=0.041). Additionally, tumor MVD was associated with both COX-2 (r=0.32, p=0.008) and VEGF (r=0.39, p=0.001) expressions. Our results showed that overexpression of COX-2 in both gastric cells and primary gastric cancer is associated with upregulation of VEGF and angiogenesis. Future studies should evaluate the potential anti-angiogenic effect of COX-2 inhibitors on human gastric cancer.en_US
dc.languageengen_US
dc.publisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/en_US
dc.relation.ispartofInternational journal of oncologyen_US
dc.subject.meshAgeden_US
dc.subject.meshAntigens, Cd34 - Biosynthesisen_US
dc.subject.meshBlotting, Westernen_US
dc.subject.meshCarcinoma - Enzymologyen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshCyclooxygenase 2en_US
dc.subject.meshDinoprostone - Metabolismen_US
dc.subject.meshFemaleen_US
dc.subject.meshGenetic Vectorsen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoblottingen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshIsoenzymes - Biosynthesis - Geneticsen_US
dc.subject.meshMaleen_US
dc.subject.meshMembrane Proteinsen_US
dc.subject.meshMicrocirculationen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeovascularization, Pathologicen_US
dc.subject.meshPlasmids - Metabolismen_US
dc.subject.meshProstaglandin-Endoperoxide Synthases - Biosynthesis - Geneticsen_US
dc.subject.meshStomach Neoplasms - Enzymologyen_US
dc.subject.meshTransfectionen_US
dc.subject.meshUp-Regulationen_US
dc.subject.meshVascular Endothelial Growth Factor A - Biosynthesisen_US
dc.titleCyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.en_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid14532971-
dc.identifier.scopuseid_2-s2.0-3042674629en_US
dc.identifier.volume23en_US
dc.identifier.issue5en_US
dc.identifier.spage1317en_US
dc.identifier.epage1322en_US
dc.identifier.isiWOS:000185984700009-
dc.publisher.placeGreeceen_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridTo, KF=7101911940en_US
dc.identifier.scopusauthoridGo, MY=7101882939en_US
dc.identifier.scopusauthoridChan, KK=8599737700en_US
dc.identifier.scopusauthoridChan, FK=7202586434en_US
dc.identifier.scopusauthoridNg, EK=7201647539en_US
dc.identifier.scopusauthoridChung, SC=19642462800en_US
dc.identifier.scopusauthoridSung, JJ=24473715000en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats